CGEM vs. RLAY, SRRK, AUTL, PRME, MESO, IMTX, PROK, HUMA, CRGX, and RGNX
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Relay Therapeutics (RLAY), Scholar Rock (SRRK), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Mesoblast (MESO), Immatics (IMTX), ProKidney (PROK), Humacyte (HUMA), CARGO Therapeutics (CRGX), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
Cullinan Therapeutics (NASDAQ:CGEM) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Cullinan Therapeutics has a net margin of 0.00% compared to Relay Therapeutics' net margin of -1,263.49%. Cullinan Therapeutics' return on equity of -28.65% beat Relay Therapeutics' return on equity.
Cullinan Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics received 4 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 79.55% of users gave Cullinan Therapeutics an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cullinan Therapeutics currently has a consensus price target of $32.00, indicating a potential upside of 40.85%. Relay Therapeutics has a consensus price target of $22.20, indicating a potential upside of 251.82%. Given Relay Therapeutics' higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Cullinan Therapeutics.
Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.
In the previous week, Cullinan Therapeutics had 8 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Cullinan Therapeutics and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.45 indicating that Relay Therapeutics is being referred to more favorably in the news media.
Summary
Cullinan Therapeutics and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
